Skip to main content
. 2020 Jul 28;8:787. doi: 10.3389/fbioe.2020.00787

FIGURE 3.

FIGURE 3

PLN vaccine prevents tumor growth in murine cancer models with a prophylactic setting. (A) Regimens of PLN vaccine tested in C57BL/6 mice. (B) Longitudinal study of percentages of SIL-positive CD8+ T cells among peripheral blood mononuclear cells (PBMCs) on day -1 before and day 10 after tumor inoculation. (C) Percentages of SIL-positive CD8+ T cells among PBMCs, spleens (SP) and lymph node (LN) on day 19. (D) Mean percentages of SIL-positive effector CD8+ T cells. (E) The frequency of KLRG1-positive subsets from SIL-positive CD8+ T cells. (F) Percentages of SIINFEKL-specific CD25+ Tregs on day 19. (G) The size of E.G7-OVA tumors was monitored over time. (H) Survival curve of immunized mice inoculated with E.G7-OVA tumor cells. Data are representative of two independent experiments. Experimental groups consisted of five mice. *P < 0.05, ***P < 0.001, and ****P < 0.0001 analyzed by one-way ANOVA (B–F) or two-way ANOVA (G–H) with Tukey’s multiple comparisons post-test.